The present invention provides a Lactococcus lactis subspecies lactis isolate WFLU-12 with the accession number o KCTC 13180BP, and a use thereof.

A composition of fecal material is prepared and administered to a subject suffering from alcohol craving, alcohol consumption and/or alcohol use disorder. The donor fecal material is enriched in beneficial microbiota associated with reduced alcohol craving and/or consumption and supplies beneficial microbiota in which the recipient is deficient, and reduces harmful microbes. Methods of preparing and administering are disclosed, along with the identification of beneficial and harmful microbiota families. The treatment is also useful for delivery of microbiota that are short chain fatty acid producers to reduce alcohol craving and/or consumption in subjects deficient in short chain fatty acids.

A composition of fecal material is prepared and administered to a subject suffering from alcohol craving, alcohol consumption and/or alcohol use disorder. The donor fecal material is enriched in beneficial microbiota associated with reduced alcohol craving and/or consumption and supplies beneficial microbiota in which the recipient is deficient, and reduces harmful microbes. Methods of preparing and administering are disclosed, along with the identification of beneficial and harmful microbiota families. The treatment is also useful for delivery of microbiota that are short chain fatty acid producers to reduce alcohol craving and/or consumption in subjects deficient in short chain fatty acids.

The invention provides compositions that include isolated, non-pathogenic, hydrogen peroxide-producing bacterial strains and genetically engineered LDH-deficient bacterial strains, which can be used to whiten teeth and treat periodontal disease.

The invention provides compositions that include isolated, non-pathogenic, hydrogen peroxide-producing bacterial strains and genetically engineered LDH-deficient bacterial strains, which can be used to whiten teeth and treat periodontal disease.

The present invention relates to a composition comprising as an active ingredient a strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity; and to a food composition and a health functional food each comprising the active ingredient. The strain having excellent ability to produce formic acid according to the present invention not only has effects of reducing body weight and inhibiting fat accumulation in organs, but also has activity to effectively lower blood triglyceride and cholesterol levels, and therefore, the composition comprising the strain as an active ingredient can be favorably used as a composition capable of preventing/alleviating or treating obesity or metabolic syndromes caused by obesity. Therefore, the strain having excellent ability to produce formic acid according to the present invention can be favorably used as a material for a medical product or health food.

The present invention relates to a composition comprising as an active ingredient a strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity; and to a food composition and a health functional food each comprising the active ingredient. The strain having excellent ability to produce formic acid according to the present invention not only has effects of reducing body weight and inhibiting fat accumulation in organs, but also has activity to effectively lower blood triglyceride and cholesterol levels, and therefore, the composition comprising the strain as an active ingredient can be favorably used as a composition capable of preventing/alleviating or treating obesity or metabolic syndromes caused by obesity. Therefore, the strain having excellent ability to produce formic acid according to the present invention can be favorably used as a material for a medical product or health food.

Provided are SpdE polypeptides and variants and nucleic acids encoding the SpdE polypeptides and variants. Also provided are vectors including one or more nucleic acids encoding a SpdE polypeptide or variant and cells including a nucleic acid encoding the SpdE polypeptide or variant, as well as cells expressing a SpdE polypeptide or variant and compositions including such cells and a pharmaceutically acceptable carrier. Finally, methods of detecting presence and/or amount of one or more amino acids in a sample are provided. The methods include contacting the sample with a SpdE protein, measuring diguanylate cyclase activity of the SpdE protein; and comparing the diguanylate cyclase activity of the SpdE protein to a control. The methods can utilize isolated SpdE protein or a cell expressing a SpdE protein.

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD).

There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

A pre-fermented symbiotic matrix based on a cereal suspension containing encapsulated probiotics and prebiotics, the manufacturing process and the corresponding use are disclosed. The invention complements the actual functional food market solving problems inherent to reduced shelf-life of foods due to loss of probiotic viability to values below the minimum limits needed to promote biological activity. The invention also improves the enzymatic process in the preparation of the cereal base and the fermentative process conditions at different levels, namely the ability to control the concentration of sugars in the cereal suspension without adding sugars, increase protein and fiber content, reduce fermentation time to reduce energy consumption during the process and reduce the risk of contamination as well as promote long term microbial stability maintenance. The invention is designed for cases where intolerance and/or allergy to dairy products occur, as wells for the pharmaceutical, cosmetic and food industries, including pet food.